Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst

Core Viewpoint - Bank of America initiated coverage on Ligand Pharmaceuticals, highlighting the company's unique royalty model and potential for significant upside [1] Ligand's Differentiated Model - Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, providing financing to biopharma developers while licensing its portfolio technologies [2] - The company is supported by experienced management and a proven investment team, positioning it to achieve ambitious revenue and earnings growth targets [2] - Ligand offers investors exposure to biopharma growth opportunities with a comparatively lower risk profile [2] Revenue and Earnings Performance - Ligand's current portfolio includes 12 major commercial-stage assets that generate the majority of its royalty revenues, expected to support profit and loss in the near to mid-term [3] - Analyst Jason Zemansky noted that Ligand has over 100 programs that could provide additional revenues and access to over $1 billion in deployable capital [3] - The company reported fourth-quarter adjusted earnings of $2.02 per share, exceeding the consensus estimate of $1.56, with sales of $59.7 million, surpassing the Wall Street estimate of $55.6 million [4] - Ligand reaffirmed its fiscal 2026 adjusted earnings guidance of $8.00-$9.00 per share, compared to the consensus of $8.29, and maintained sales guidance between $245 million and $285 million, against a consensus of $265.7 million [4] Valuation and Growth Potential - Bank of America stated that Ligand is well-positioned for future success, with higher margins than traditional biopharma firms due to its lack of extensive infrastructure for drug development [5] - Ligand's 5-year growth rates are notable, with expected top- and bottom-line CAGRs of +5% and +12%, respectively, compared to large-cap peers in the pharma and biotech sectors [6] - Ligand's stock increased by 4.30% to $221.42 as of the last check on Wednesday [6]